Maja Katalinić

Dr. Maja Katalinić

Institute for Medical Research and Occupational Health, Zagreb, Croatia
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2018 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
TZTamara Zorbaz
Tamara Zorbaz
ABAnissa Braïki
Anissa Braïki
NMNikola Maraković
Nikola Maraković
JRJulien Renou
Julien Renou
EMEugenio de la Mora
Eugenio de la Mora
Pierre-Yves RenardPierre-Yves Renard
Pierre-Yves Renard

24 June 2020 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
AZAntonio Zandona
Antonio Zandona
Maja KatalinićMaja Katalinić
Maja Katalinić
Goran ŠinkoGoran Šinko
Goran Šinko
AKAndreja Radman Kastelic
Andreja Radman Kastelic
IPInes Primozic
Ines Primozic
Zrinka KovarikZrinka Kovarik
Zrinka Kovarik

22 July 2017 in Molecules
Verified
Journal Article
Open access
PDF file
Maja KatalinićMaja Katalinić
Maja Katalinić
AZAntonio Zandona
Antonio Zandona
ARAlma Ramic
Alma Ramic
TZTamara Zorbaz
Tamara Zorbaz
IPInes Primozic
Ines Primozic
Zrinka KovarikZrinka Kovarik
Zrinka Kovarik
For the last six decades, researchers have been focused on finding efficient reactivators of organophosphorus compound (OP)-inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). In this study, we have focused our research on a new oxime scaffold based on the Cinchona structure since it was proven to fit the cholinesterases active site and reversibly inhibit their activity. Three Cinchona oximes (C1, C2, and C3), derivatives of the 9-oxocinchonidine, were synthesized and investigated in reactivation of various OP-inhibited AChE and BChE. As the results showed, the tested oximes were more efficient in the reactivation of BChE and they reactivated enzyme activity to up to 70% with reactivation rates similar to known pyridinium oximes used as antidotes in medical practice today. Furthermore, the oximes showed selectivity towards binding to the BChE active site and the determined enzyme-oxime dissociation constants supported work on the future development of inhibitors in other targeted studies (e.g., in treatment of neurodegenerative disease). Also, we monitored the cytotoxic effect of Cinchona oximes on two cell lines Hep G2 and SH-SY5Y to determine the possible limits for in vivo application. The cytotoxicity results support future studies of these compounds as long as their biological activity is targeted in the lower micromolar range.

26 June 2021 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
AZAntonio Zandona
Antonio Zandona
NMNikola Maraković
Nikola Maraković
PMPetra Mišetić
Petra Mišetić
Josip MadunicJosip Madunic
Josip Madunic
KMKatarina Miš
Katarina Miš
Maja KatalinićMaja Katalinić
Maja Katalinić

20 March 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AMAna Matošević
Ana Matošević
AKAndreja Radman Kastelic
Andreja Radman Kastelic
AMAna Mikelic
Ana Mikelic
AZAntonio Zandona
Antonio Zandona
Maja KatalinićMaja Katalinić
Maja Katalinić
THTomica Hrenar
Tomica Hrenar
The treatment of central nervous system (CNS) diseases related to the decrease of neurotransmitter acetylcholine in neurons is based on compounds that prevent or disrupt the action of acetylcholinesterase and butyrylcholinesterase. A series of thirteen quinuclidine carbamates were designed using quinuclidine as the structural base and a carbamate group to ensure the covalent binding to the cholinesterase, which were synthesized and tested as potential human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors. The synthesized compounds differed in the substituents on the amino and carbamoyl parts of the molecule. All of the prepared carbamates displayed a time-dependent inhibition with overall inhibition rate constants in the 103 M−1 min−1 range. None of the compounds showed pronounced selectivity for any of the cholinesterases. The in silico determined ability of compounds to cross the blood–brain barrier (BBB) revealed that six compounds should be able to pass the BBB by passive transport. In addition, the compounds did not show toxicity toward cells that represented the main models of individual organs. By machine learning, the most optimal regression models for the prediction of bioactivity were established and validated. Models for AChE and BChE described 89 and 90% of the total variations among the data, respectively. These models facilitated the prediction and design of new and more potent inhibitors. Altogether, our study confirmed that quinuclidinium carbamates are promising candidates for further development as CNS-active drugs, particularly for Alzheimer’s disease treatment.

1 June 2023 in Archives of Industrial Hygiene and Toxicology
Verified
Journal Article
Open access
PDF file
ALAna-Marija Lulić
Ana-Marija Lulić
Maja KatalinićMaja Katalinić
Maja Katalinić
This paper brings a brief review of the human patatin-like phospholipase domain-containing protein (PNPLA) family. Even though it consists of only nine members, their physiological roles and mechanisms of their catalytic activity are not fully understood. However, the results of a number of knock-out and gain- or loss-of-function research models suggest that these enzymes have an important role in maintaining the homeostasis and integrity of organelle membranes, in cell growth, signalling, cell death, and the metabolism of lipids such as triacylglycerol, phospholipids, ceramides, and retinyl esters. Research has also revealed a connection between PNPLA family member mutations or irregular catalytic activity and the development of various diseases. Here we summarise important findings published so far and discuss their structure, localisation in the cell, distribution in the tissues, specificity for substrates, and their potential physiological role, especially in view of their potential as drug targets.